Form 4: Cullinan Therapeutics' Chief Scientific Officer Jennifer Michaelson Executes Stock Option and Sells Shares

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, exercised stock options and sold shares of common stock on May 6th and 7th, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 6th and 7th, 2024, Jennifer Michaelson, the Chief Scientific Officer of Cullinan Therapeutics, exercised stock options to acquire shares of common stock.
• Ms. Michaelson then sold a portion of these shares on the same days.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 5, 2024.
• On May 6th, 50,000 shares were acquired via option exercise at a price of $4.30 per share, and 37,723 shares were sold at a weighted average price of $27.82 and 20,277 shares were sold at a weighted average price of $28.54.
• On May 7th, 5,606 shares were acquired via option exercise at a price of $4.30 per share, and 5,606 shares were sold at a weighted average price of $30.06.
• Following these transactions, Ms. Michaelson directly owns 129,582 shares of Cullinan Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are part of a pre-arranged trading plan, suggesting they are not necessarily indicative of the officer's sentiment about the company's future prospects.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates